Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,050.00
Bid: 12,038.00
Ask: 12,040.00
Change: -106.00 (-0.87%)
Spread: 2.00 (0.017%)
Open: 12,092.00
High: 12,178.00
Low: 12,010.00
Prev. Close: 12,156.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 4-EU loses bid for speedier AstraZeneca vaccine deliveries

Fri, 18th Jun 2021 14:06

* Judge orders AstraZeneca to deliver doses by strict
deadlines

* EU had asked for more doses to be shipped earlier

* AstraZeneca may have breached contract in reserving doses
for UK

* Second legal case will establish whether contract was
breached
(Adds details from ruling)

By Francesco Guarascio and Alistair Smout

BRUSSELS/LONDON, June 18 (Reuters) - The European Union on
Friday lost its bid to speed up deliveries of AstraZeneca's
COVID-19 vaccines, the first of its legal challenges
against the drugmaker that rocked the bloc as it scrambled to
shore up supplies.

AstraZeneca said the EU had lost its legal case, but
European Commission President Ursula von der Leyen said the
court ruling supported its view that the Anglo-Swedish
pharmaceutical giant had failed to honour its commitments.

The row plunged the EU into crisis earlier this year as
states, under pressure to speed up vaccinations, scrambled for
shots. Brussels has since largely cut ties with AstraZeneca,
choosing not to buy any more of its vaccines for now.

The drugmaker had committed to do its best to deliver 300
million doses to the 27-nation bloc by the end of June, but
production delays led it to revise this to 100 million vaccines.

This delayed the EU's vaccination drive as the bloc had
initially bet on AstraZeneca to deliver the largest volume,
sparking a bitter row and EU legal action to get at least 120
million doses by the end of June.

However, the judge ruled that AstraZeneca must deliver only
80.2 million doses by a deadline of Sept. 27. The drugmaker said
it would "substantially exceed" that by the end of June.

The court said in a statement that AstraZeneca must deliver
15 million doses by July 26, another 20 million by Aug. 23 and a
further 15 million by Sept. 27, to reach a total of 50 million
doses, which are in addition to 30 million that had been given
to the EU when the legal case began.

Should it miss the deadlines in the ruling, AstraZeneca
would face a penalty of "10 euros ($11.8) per dose not
delivered", the judge said, less than the 10 euros per dose per
day fine the EU had sought in bringing its legal action.

AstraZeneca will remain bound to do its best to deliver 300
million doses to the EU, without a precise timetable, and a new
hearing is to be held in September when compliance with the
contract will be assessed again, the ruling said.

SERIOUS BREACH

An EU lawyer also said the judgment meant that as a proof of
best effort AstraZeneca will have to deliver COVID-19 vaccines
from a factory in Britain, if needed to meet its EU commitments.

The company had said it could not immediately deliver to the
EU doses from an Oxford BioMedica factory because it had to
supply Britain first.

The ruling said that AstraZeneca may have committed a
serious breach of the contract by reserving Oxford BioMedica's
output for the British market. However a final decision on this
will be made in a second legal case.

AstraZeneca said the court had found that the EU had no
exclusivity or right of priority over other parties.

"The judgment also acknowledged that the difficulties
experienced by AstraZeneca in this unprecedented situation had a
substantial impact on the delay," it said in a statement.

"AstraZeneca now looks forward to renewed collaboration with
the European Commission to help combat the pandemic in Europe."

The EU last month launched a second legal action against
AstraZeneca over an alleged breach of the supply contract, which
will continue after the summer. Friday's ruling was over whether
AstraZeneca had to speed up vaccine deliveries.
(Reporting by Francesco Guarascio in Brussels, Alistair Smout
in London, additional reporting by Muvija M in Bengaluru;
Editing by David Evans, Catherine Evans, Louise Heavens,
Alexander Smith and Barbara Lewis)

More News
8 Feb 2024 08:59

LONDON MARKET OPEN: Unilever up on buyback; BAT ups dividend

(Alliance News) - THE FTSE 100 in London opened slightly higher on Thursday, with earnings from British American Tobacco and Unilever boosting the index.

Read more
8 Feb 2024 08:44

TOP NEWS: AstraZeneca confident after 2023 profit more than doubles

(Alliance News) - AstraZeneca PLC on Thursday said it expects another year of strong growth after reporting pretax profit in 2023 more than doubled.

Read more
8 Feb 2024 07:58

AstraZeneca shares slip as Q4 profits miss forecasts

(Sharecast News) - Biopharma titan AstraZeneca delivered a 6% increase in sales in 2023 despite a $3.7bn decline in Covid-19 medicines revenues, as it guided to a strong pick-up in growth this year - though profits came in slightly under analysts' forecasts.

Read more
8 Feb 2024 07:50

LONDON BRIEFING: Unilever sets new buyback; Astra profit surges

(Alliance News) - Stocks in London are called to open slightly higher on Thursday, as investors eye a busy day of earnings.

Read more
2 Feb 2024 08:38

AstraZeneca celebrates latest successful trial of acoramidis in Japan

(Alliance News) - AstraZeneca PLC on Friday said positive results from a Phase 3 trial of acoramidis are consistent with global findings, bring the drug closer to regulatory submission in Japan.

Read more
2 Feb 2024 06:22

TOP NEWS: US sends drugmakers initial offers in Medicare price talks

(Alliance News) - The US government said it was making initial offers to drugmakers Thursday as part of Medicare negotiations meant to lower the prices many older Americans would pay for 10 medicines.

Read more
1 Feb 2024 15:52

UK earnings, trading statements calendar - next 7 days

Friday 2 February 
YouGov PLCTrading Statement
Monday 5 February 
Home REIT PLCTrading Statement
Porvair PLCFull Year Results
Trident Royalties PLCTrading Statement
Vodafone Group PLCTrading Statement
Tuesday 6 February 
Alumasc Group PLCHalf Year Results
BP PLCFull Year Results
Filtronic PLCHalf Year Results
Mattioli Woods PLCHalf Year Results
Renishaw PLCHalf Year Results
Virgin Money UK PLCTrading Statement
Wednesday 7 February 
Ashmore Group PLCHalf Year Results
Barratt Developments PLCHalf Year Results
HydrogenOne Capital Growth PLCTrading Statement
Phoenix Spree Deutschland LtdTrading Statement
PZ Cussons PLCHalf Year Results
Smurfit Kappa Group PLCFull Year Results
UK Commercial Property REIT LtdTrading Statement
Thursday 8 February 
Anglo American PLCTrading Statement
AstraZeneca PLCFull Year Results
British American Tobacco PLCFull Year Results
Compass Group PLCTrading Statement
Redrow PLCHalf Year Results
SSE PLCTrading Statement
Unilever PLCFull Year Results
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
29 Jan 2024 08:19

TOP NEWS: AstraZeneca, Daiichi's Enhertu granted priority review in US

(Alliance News) - AstraZeneca PLC on Monday said its cancer drug conjugate received priority review by the Food & Drug Administration in the US for patients with metastatic HER2-positive solid tumours.

Read more
22 Jan 2024 11:45

BioNTech challenges AstraZeneca with breast cancer precision drug trial

FRANKFURT, Jan 22 (Reuters) - BioNTech and its partner Duality Biologics said on Monday they initiated a late-stage trial testing their precision drug against a certain type of breast cancer, taking on a rival partnership between AstraZeneca and Daiichi Sankyo.

Read more
19 Jan 2024 09:28

TOP NEWS: AstraZeneca's Voydeya receives approval in Japan for PNH

(Alliance News) - AstraZeneca PLC on Friday said its inhibitor Voydeya, also known as danicopan, received approval in Japan for adults with paroxysmal nocturnal haemoglobinuria, or PNH.

Read more
16 Jan 2024 17:17

FTSE 100 hits one-month low, precious miners biggest drag

FTSE 100 down 0.5%, FTSE 250 flat

*

Read more
16 Jan 2024 16:17

London close: Stocks finish lower as wage growth eases

(Sharecast News) - London's stock markets finished in the red on Tuesday, as investors assessed the latest UK jobs data.

Read more
16 Jan 2024 11:58

LONDON MARKET MIDDAY: FTSE 100 falls despite cooler UK wage growth

(Alliance News) - The FTSE 100 in London was down at midday Tuesday, as investors nervously eye Wednesday's UK inflation data and what it will mean for interest rates.

Read more
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
16 Jan 2024 08:15

UBS downgrades AstraZeneca to 'sell'

(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.